Tumor Transcriptomics - Global Strategic Business Report

The global market for Tumor Transcriptomics was estimated at US$5.8 Billion in 2024 and is projected to reach US$7.6 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Tumor Transcriptomics market.

Global Tumor Transcriptomics Market - Key Trends & Drivers Summarized

What Is the Role of Transcriptomics in Understanding Tumor Biology?

Tumor transcriptomics decodes active gene expression in cancer cells, revealing how tumors behave and evolve. Unlike static DNA data, transcriptomics captures dynamic molecular events, identifying gene activity that influences tumor growth, metastasis, and therapy resistance.

It`s pivotal in precision medicine, allowing oncologists to customize treatment based on real-time tumor behavior. Single-cell and spatial transcriptomics provide high-resolution maps of cellular differences within tumors, improving the understanding of heterogeneity and guiding therapy.

How Are Technology and Clinical Adoption Expanding the Transcriptomics Frontier?

Technological leaps in sequencing platforms and data analytics have brought transcriptomics into clinical practice. Tools like spatial transcriptomics reveal how different parts of a tumor interact with the surrounding tissue. RNA-based profiling is now being used to match patients with immunotherapies, targeted drugs, or chemotherapies.

Regulatory agencies are approving transcriptomic panels for cancer diagnosis and prognosis. Partnerships between hospitals and biotech firms are accelerating integration into everyday oncology care. AI and cloud platforms are making data interpretation faster and more accessible.

The Growth in the Tumor Transcriptomics Market Is Driven by Several Factors

Growth is driven by the rise of precision oncology, falling costs of RNA sequencing, and wider clinical adoption. Increasing cancer prevalence and the demand for biomarker-driven therapies are key drivers. Government funding, omics infrastructure investment, and the expanding pipeline of RNA-targeting drugs all contribute to market momentum.

Scope Of Study:

The report analyzes the Tumor Transcriptomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Product (Consumables, Instruments, Software & Services); Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Tumor Types); Technology (Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology, Other Technologies); Application (Diagnostics & Disease Profiling Application, Drug Discovery Application, Other Applications); End-Use (Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Consumables segment, which is expected to reach US$4.3 Billion by 2030 with a CAGR of a 5.0%. The Instruments segment is also set to grow at 3.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $1.6 Billion in 2024, and China, forecasted to grow at an impressive 7.3% CAGR to reach $1.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Tumor Transcriptomics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Tumor Transcriptomics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Tumor Transcriptomics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as 10x Genomics, Agilent Technologies, Inc., Akoya Biosciences, Inc., Arraystar Inc., Bio-Rad Laboratories, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Tumor Transcriptomics market report include:

• 10x Genomics
• Agilent Technologies, Inc.
• Akoya Biosciences, Inc.
• Arraystar Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• CD Genomics
• Cytiva (Danaher)
• F. Hoffmann-La Roche AG
• Fluidigm Corporation (now Standard BioTools)
• GenScript Biotech Corporation
• Illumina, Inc.
• Lexogen GmbH
• NanoString Technologies, Inc.
• Novogene Co., Ltd.
• Oxford Nanopore Technologies
• Qiagen N.V.
• Sequentia Biotech
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.